-
公开(公告)号：US10813989B2
公开(公告)日：2020-10-27
申请号：US16704701
申请日：2019-12-05
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , A61K31/7028 , A61K47/10 , A61K47/18 , C07K14/22 , C07K16/12 , A61K47/26 , A61K47/64 , A61P31/00 , A61K39/12 , A61K39/00
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
公开(公告)号：US10183070B2
公开(公告)日：2019-01-22
申请号：US15883334
申请日：2018-01-30
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , A61K31/7028 , A61K47/10 , A61K47/18 , C07K14/22 , C07K16/12 , A61K47/26 , A61K47/64 , A61P31/00
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
公开(公告)号：US20240299523A1
公开(公告)日：2024-09-12
申请号：US18660419
申请日：2024-05-10
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Leena Shriram Bagle , Amardeep Singh Bhupender Bhalla , Miguel Angel Garcia , Lei Hu , Lakshmi Khandke , Avvari Krishna Prasad , Cindy Xudong Yang
CPC classification number: A61K39/092 , A61K39/39 , A61K2039/545 , A61K2039/55 , A61K2039/55505 , A61K2039/6031 , A61K2039/6037 , A61K2039/6068 , A61K2039/70
Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US12016913B2
公开(公告)日：2024-06-25
申请号：US17474561
申请日：2021-09-14
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Leena Shriram Bagle , Amardeep Singh Bhupender Bhalla , Miguel Angel Garcia , Lei Hu , Lakshmi Khandke , Avvari Krishna Prasad , Cindy Xudong Yang
CPC classification number: A61K39/092 , A61K39/39 , A61K2039/545 , A61K2039/55 , A61K2039/55505 , A61K2039/6031 , A61K2039/6037 , A61K2039/6068 , A61K2039/70
Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20230414737A1
公开(公告)日：2023-12-28
申请号：US18343968
申请日：2023-06-29
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , C07K14/22 , C07K16/12 , A61K47/18 , A61K47/10 , A61K47/26 , A61K31/7028 , A61K47/64 , A61P31/00 , A61K39/12
CPC classification number: A61K39/095 , C07K14/22 , C07K16/1217 , A61K47/183 , A61K47/10 , A61K47/26 , A61K31/7028 , A61K47/6415 , A61K47/646 , A61P31/00 , A61K39/12 , A61K2039/545
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
Patent Agency Ranking
公开(公告)号：US11147865B2
公开(公告)日：2021-10-19
申请号：US16984499
申请日：2020-08-04
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Leena Shriram Bagle , Amardeep Singh Bhupender Bhalla , Miguel Angel Garcia , Lei Hu , Lakshmi Khandke , Avvari Krishna Prasad , Cindy Xudong Yang
Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US10888611B2
公开(公告)日：2021-01-12
申请号：US15543232
申请日：2016-02-16
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: A61K39/095 , A61K47/64 , A61K39/00 , C07K14/12 , A61K39/295 , A61K39/12 , A61K39/05 , A61K39/08 , A61K39/04 , C07K14/22 , A61K47/02 , A61K47/22 , A61K47/26
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US09822150B2
公开(公告)日：2017-11-21
申请号：US14470922
申请日：2014-08-27
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: A61K39/00 , C07K14/22 , A61K39/095 , A61K39/12 , A61K39/39 , C12N7/00 , A61K39/13 , A61K39/295
CPC classification number: C07K14/22 , A61K39/0016 , A61K39/095 , A61K39/12 , A61K39/13 , A61K39/295 , A61K39/39 , A61K2039/5252 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/70 , C12N7/00 , C12N2710/20034 , C12N2770/32634 , Y02A50/466
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20210101943A1
公开(公告)日：2021-04-08
申请号：US17126712
申请日：2020-12-18
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: C07K14/22 , A61K39/13 , A61K39/295 , A61K39/00 , A61K39/095 , A61K39/12 , A61K39/39 , C12N7/00
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US10946086B2
公开(公告)日：2021-03-16
申请号：US16245378
申请日：2019-01-11
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G. K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.02 seconds)
